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myeloablative regimens, especially total body irradiation, result
in lasting growth disturbance, high risk of alloimmune disease,
second cancers and early mortality, as described in the editorial
and the reference cited above. For this reason, HSCT does not
and by its very nature will not fulfill the second goal.
With regard to the third goal, there is no realistic possibility
that HSCT can ever meet this because of its high consumption of
costly human and material health resources in this nation and a
world so deficient in them, as reflected in the maternal and child
health statistics of this nation and the millions of deaths of
mothers, infants and children globally that could be easily
prevented or successfully treated by simple low cost measures.
Twenty-five years ago, it became apparent that treatment of
childhood acute leukemias needed to be targeted to their genetic
disorders.6 The ‘sledge hammer,’ hazardous, resource-consuming
non-specific measures such as combination chemotherapy, radia-
tion and HSCT must be replaced by specific gene-targeted
approaches. Two highly effective and minimally toxic gene-
targeted treatments, tretinoin for acute promyelocytic leukemia
and imatinib mesylate for Ph-positive chronic myelocytic leukemia
and ALL, were developed in the late 1980s and early 1990s.7,8
Now in general use, they demonstrate the value of this approach.
However, basic and clinical research for other agents targeted
to specific genetic aberrations in leukemia has been slow to
develop.
The data of the Children’s Cancer Group concerning survival
of children with ALL published by Nguyen et al.9 included
nearly 10 000 patients treated over 20 years.9 They show no
significant improvement in 5-year event-free survival of children
treated for ALL over this period. It is time for diversion of federal
and private research funds from large expensive studies of
relatively minute details of ‘sledge hammer therapy’ and flawed
comparisons that have not yielded significant improvement in
cure rates in recent years to basic laboratory and clinical
research to identify specific gene-targeted agents that are not
only effective but safer and more likely to be accessible to all
children.
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Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary
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About sixty-percent of patients with primary myelofibrosis (PMF)
harbor the JAK2V617F mutation while about 8–10% present a
mutation at codon 515 in MPL exon 10, W515L/K/A.1 These
mutations are shared by the other Philadelphia-chromosome
negative myeloproliferative neoplasms (MPNs), which include
polycythemia vera (PV), essential thrombocythemia (ET), and
refractory anemia with ring sideroblasts and thrombocytosis
(RARS-T), and represent a major criteria for MPN diagnosis
according to the 2008 WHO classification.2 Presence of a
JAK2V617F mutated genotype and/or higher V617F allele
burden have been variably associated with hematological
and clinical characteristics in patients with PV or ET.3 In case
of PMF, a significant association of JAK2V617F mutated status
with a more pronounced myeloproliferative phenotype favoring
raised hemoglobin level and leukocyte count and larger
splenomegaly has been reported, although not universally.3
However, the most relevant finding in two independent studies
in PMF patients, was that a low JAK2 allele burden at diagnosis
represented a strong surrogate marker associated with shortened
survival.4,5
Overall prognosis in PMF is poorer compared to other classic
MPNs. An international prognostic score system (IPSS), which
allows to discriminate four categories of patients with signifi-
cantly different median survival, has been developed recently by
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the International Working Group for Myelofibrosis Research and
Treatment (IWG-MRT).6 However, identification of additional
factors associated with prognosis is of considerable importance
for driving therapeutic decisions. For example, cytogenetic
abnormalities have an IPSS-independent value.7 Furthermore,
Tefferi et al.8 recently reported that nullizygosity for the JAK2
46/1 haplotype was associated with inferior survival regardless
of IPSS score or V617F allele burden.
The 46/1, or ‘GGCC’ haplotype, has been characterized in
three independent studies as a germline haplotype block that
is strongly associated (3–4 odds ratio) with the development
of a JAK2V617F-mutated MPN.9–11 Subsequent studies also
showed significant association of this haplotype, with JAK2 exon
12-mutated,12 JAK2-wild type ET,13 and MPLW515-mutated
PMF or ET,14 suggesting that this haplotype increases the risk of
developing a MPN, regardless of the acquisition of the V617F
mutation. However, in another recent study, no such association
with MPL mutations was described.15
The aim of this study was to evaluate the association of JAK2
46/1 haplotype with JAK2V617F mutational status, clinical
characteristics and prognosis in a series of patients with PMF.
We obtained permission from the local institutional review
board of the two institutions where the patients were referred to.
We included 202 patients with a diagnosis of PMF according
to the 2008 World Health Organization (WHO) criteria; in the
case diagnosed earlier, a careful review of the clinical records
and of the bone marrow biopsy was performed to assure
compliance with the WHO criteria. All were typical fibrotic
forms of myelofibrosis; pre-fibrotic myelofibrosis were not
included. Measurement of JAK2V617F allele burden was
performed in genomic DNA purified from granulocytes,
obtained within one year from diagnosis in the absence of
cytotoxic therapy, using a quantitative real time (QRT-PCR)
assay, as previously described.5 Genotyping for MPL W515L/K
mutation was performed as described.16 Screening for 46/1
haplotype was performed in granulocytic DNA using a tag SNP,
rs12343867, that is in complete linkage disequilibrium with the
46/1 haplotype. A commercially available SNP RT-PCR assay
(No. C_31941689_10, Applied Biosystem, Foster City, CA, USA;
http://www2.appliedbiosystems.com) was employed in an
allelic discrimination assay using the Abi Prism 7300 Detection
System. This SNP consists in a T to C shift, with the C allele
being associated with the 46/1 haplotype. We used published
criteria9 for scoring SNPs as homozygous or heterozygous, to
cope for skewed allelic ratio caused by uniparental disomy
(UPD) at JAK2 locus in cases with large homozygous JAK2
V617F mutated clone. In 11 patients with 490% JAK2V617F
allele who were homozygous for either C (n¼ 6) or T (n¼ 5)
allele, only one allele was included in the final analysis,
considering that no SNP information could be obtained for the
residual JAK2 wild-type allele.9
The JAK2 mutated allele burden and the rs12343867 CC, TT,
or CT variants were considered as ordered categorical variables.
The chi-square or Fisher’s exact test (two-tailed) or chi-square
test for trend (larger contingency table) with Bonferroni
correction, were used to compare the variables among the
different groups of patients which had been categorized
according to mutational status, haplotype status, or mutated
allele burden. The analysis of continuous variables among
the groups was performed using the Mann–Whitney U test or
Kruskal–Wallis test for multiple comparison. Kaplan–Meier
analysis and the log-rank test were used to estimate overall
survival. A P value of o0.05 was considered to indicate
statistical significance; all tests were two-tailed. Data were
processed using the SPSS (Statsoft Inc, Tulsa, OK, USA) software.
The main clinical and laboratory characteristics of the 202
PMF patients included in the study are reported in Table 1.
Median follow-up was 65.4 months, ranging from 1 to 312
Table 1 Characteristics of the 202 patients with PMF included in the study, stratified according to the rs12347867 genotype
rs 12347867 genotype P
All patients CC CT TT
No. 202 39 84 79
Agea 58 (16–90) 60 (16–83) 57 (26–90) 57 (19–89) 0.38
Follow-up, monthsb 65.6 (1–312) 58.5 (2.4–237.3) 68.5 (3.0–312.0) 66.2 (1.0–308.9) 0.51
Females, no. (%) 75 (37.1) 21 (53.8) 30 (35.7) 24 (30.3) 0.05
JAK2V617F, no (%) 133 (65.8) 31 (79.5) 56 (64.3) 48 (60.7) 0.13
JAK2V617F burdena 50 (5–100) 63 (11–100) 53 (12–100) 46 (5–100) 0.06
WBC  109/la 9.3 (0.6–106.1) 10.6 (1.4–37.7) 8.8 (1.9–90.8) 9.3 (0.6–106.1) 0.37
Hb g/la 123 (46–180) 122 (77–170) 125 (56–175) 119 (46–180) 0.45
PLT 109/la 355 (19–2522) 346 (19–1300) 347 (38–1568) 367 (41–2522) 0.44
LDH U/la 614 (162–3426) 757 (198–2645) 602 (162–3426) 548 (202–2981) 0.65
Blast X1%, no (%)c 51 (30.2) 14 (41.2) 19 (27.1) 18 (27.7) 0.49
CD34+ cells %a 0.24 (0–9.5) 0.22 (0–5.58) 0.25 (0.01–9.5) 0.25 (0–7.55) 0.98
CD34+ cells  109/la 26.2 (0–5454) 47.0 (0–789) 22.5 (0.73–5020) 27.97 (0–5454) 0.70
Spleen 415 cm from LCM, no (%) 60 (29.7) 17 (43.6) 18 (21.4) 25 (31.6) 0.15
Constitutional symptoms, no (%)c 72 (43.7) 19 (55.9) 28 (40.0) 25 (38.4) 0.26
IWG-MRT score, no (%)c
Low 61 (36.1) 7 (20.6) 28 (40.0) 26 (40.0)
Int-1 38 (22.5) 8 (23.5) 16 (22.8) 14 (21.5) 0.40
Int-2 40 (23.7) 9 (26.5) 18 (25.7) 13 (20.0)
High 30 (17.7) 10 (29.4) 8 (11.4) 12 (18.5)
Leukemia transformation, no. (%) 25 (12.4) 4 (10.2) 11 (13.9) 10 (12.6) 0.95
Deaths, no (%) 42 (20.8) 11 (28.2) 14 (16.7) 16 (20.2) 0.33
Abbreviations: PMF, primary myelofibrosis; IWG-MRT, Intenational Working Group for Myelofibrosis Research and Treatment.
aValues are expressed as the median (range).
bValues expressed as the mean (range)
cInformation were available in 169 patients.
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months; 42 patients died during the observation period (20.8%).
Leukemia transformation occurred in 25 patients (12.4%).
According to the IPSS score, 36.1, 22.5, 23.7 and 17.7% of
the evaluable patients (n¼ 169) were distributed among the
four risk categories, comparable to other series.6,8 One-hundred
thirty-three patients were JAK2V617F mutated (65.8%), with a
median allele burden of 50% (range 5–100%); their distri-
bution in V617F allele burden quartiles was 11.3, 39.1, 22.5,
and 27.1%.
The frequency of C allele, that stands for 46/1 haplotype, was
significantly higher in the whole series of PMF patients,
compared to the local control population comprising of 235
subjects (0.386 vs 0.253; P¼ 6.37 106) (Table 2). Such
difference was largely due to the category of JAK2V617F
mutated patients (C allele frequency, 0.413; P¼ 8.29 107
vs local controls). In fact, JAK2 wild-type patients displayed an
increased representation of the C allele compared to controls
(frequency, 0.333), which did not reach the level of statistical
significance if compared with local controls (P¼ 0.063).
However, if we considered the WTCCC data that included
1492 subjects, as a reference,9 also the difference with JAK2
wild-type patients reached the significance level (P¼ 0.036).
We interpret these data as supportive of the association of 46/1
haplotype with both JAK2V617F mutated and wild-type PMF
patients, although the power of association with the latter group
of patients is significantly lower and could be missed when the
number of alleles considered is relatively small. On the other
hand, we observed a significant correlation between the burden
of V617F allele and the frequency of rs12343867 allele.
In JAK2V617F mutated patients, with an allele burden lower
than 25% the frequency of C allele was 0.333, similar to
the JAK2 wild-type population (P¼ 0.331), while a C allele
frequency of 0.416 was found in those with greater than 25%
V617F allele burden (P¼ 7.83 107 vs local controls). Further-
more, by dividing JAK2V617F mutated patients in quartiles of
allele burden, the frequency of C allele increased progressively
from 0.333 to 0.500 (Po0.0001, w2 test for trend).
In our series, we found 7 JAK2V617F wild-type/MPLW515
mutated patients among 190, in whom the information was
available; two were W515K and five W515L. The frequency of C
allele was 0.50, and the difference with local controls was statistically
significant (P¼ 0.038, OR 2.95 (95% CI, 1.01–8.58)). However, the
low number of subjects considered precludes any conclusion.
We found no difference regarding hematological parameters,
large splenomegaly, presence of constitutional symptoms,
categorization according to the IPSS, rate of transformation
to leukemia or death according to the rs12343867 genotypes.
Also, we found no difference in overall survival in the three
rs12343867 genotypes even after stratification of the patients
according to their JAK2V617F mutational status (Figures 1a–c).
In the original reports, the 46/1 haplotype was found to bear
strong association with JAK2V617F-positive MPN whereas the
association with V617F-negative cases was more variable.9–11
However, in subsequent analysis from the Mayo Clinic in PMF8
and ET,13 the frequency of the rs12343867 C-allele (i.e., the
46/1 haplotype) was found significantly increased in both
V617F-mutated and wild-type patients; similar results have
been found in a large series of ET patients without V617F
mutation, either MPL exon 10 mutated or JAK2/MPL
wild-type.14 Present data in the largest PMF population analyzed
till date confirm the significant association of 46/1 haplotype
with PMF, and point to a major contribution of JAK2V617F-
mutated patients. In line with Tefferi et al.,8 we observed that the
C allele was over-represented in patients showing the highest
V617F allele burden; this underlines the contribution of UPD in
the progressively increasing rate of 46/1 haplotype according to
V617F allele burden.
Association of the rs12343867 genotype with clinical
characteristics and disease prognosis was also evaluated. We
failed to identify statistically significant correlations between
any of the possible genotypes (CC vs CT vs TT) and a number
of hematological or clinical variables. In particular, we found no
association with the rate of leukemia transformation, categories
of risk, and overall survival. These results are at variance with a
recent study, where the nullizygosity for the 46/1 haplotype, that
is, harboring the rs12343867 TT-allele, was significantly
associated with shortened survival, particularly in the group of
JAK2V617F wild-type patients.8 There is no obvious explanation
for these discrepancies. One possibly meaningful difference
relates to the fact that the number of patients who reached the
survival end-point in the Mayo Clinic study was greater than that
observed in this series (59 vs 21%). Therefore, we surmise that
additional studies are required in order to confirm whether the
germline configuration of 46/1 haplotype represents a surrogate
marker of worse prognosis in PMF patients, independent of
IPSS score.









vs local controls vs WTCCC controls
P value OR (95% CI) P value OR (95% CI)
Local controls 235 119 351 0.253 F F 0.9817 0.99 (0.80–1.25)
WTCCC 1492 757 2227 0.252 0.9817 0.99 (0.80–1.25) F F
All patients 202 156 237 0.386 6.37 106 1.94 (1.45–2.59) 1.84109 1.93 (1.55–2.41)
JAK2 wt 69 46 92 0.333 0.063 1.47 (0.98–2.22) 0.036 1.47 (1.02–2.11)
JAK2 V617F-pos 133 110 145 0.413 8.29 107 2.24 (1.62–3.09) 7.69 1010 2.23 (1.72–2.90)
V617F allele burden
o25% 15 10 20 0.333 0.331 1.47 (0.67–3.24) 0.319 1.47 (0.68–3.15)
X25% 118 98 125 0.416 7.83 107 2.31 (1.65–3.24) 1.43109 2.30 (1.75–3.04)
1–25% 15 10 20 0.333 0.434 1.47 (0.67–3.24) 0.319 1.47 (0.68–3.15)
26–50% 52 39 65 0.375 0.012 1.77 (1.13–2.77) 0.0051 1.76 (1.18–2.65)
51–75% 30 25 35 0.416 0.007 2.11 (1.21–3.66) 0.004 2.10 (1.25–3.53)
76–100% 36 36 25 0.500 5.14 108 4.25 (2.45–7.37) 3.07109 4.23 (2.52–7.10)
Abbreviation: WTCCC, Wellcome Trust Case Control Consortium.9
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Figure 1 Kaplan–Meier analysis of overall survival in PMF patients.
The plots show the overall survival according to the rs12343867
genotype (CC corresponds to homozygosity for the 46/1 haplotype) in
all 202 PMF patients (a), in the 69 JAK2 wild-type patients (b) or in the
133 JAK2V617F mutated patients (c).
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Bone marrow fibrosis and vascular density lack prognostic significance in childhood
acute lymphoblastic leukaemia
Leukemia (2010) 24, 1537–1538; doi:10.1038/leu.2010.134;
published online 10 June 2010
Three recent papers by Nore´n-Nystro¨m et al.1–3 have collectively
shown that higher levels of bone marrow fibrosis (measured as
reticulin fibrin density (RFD)) and increased vascularity (micro-
vessel density (MVD)) are associated with both relapse and higher
minimal residual disease (MRD) in precursor B acute lympho-
blastic leukaemia. Other studies have reported marrow fibrosis4
or increased vascularity5 in some acute lymphoblastic leukaemia
(ALL) patients, but have not found a prognostic significance
associated with higher levels.
To resolve this controversy and to determine whether RFD
and/or MVD has a clinically useful prognostic role in our
patients, we measured fibrosis, RFD and MVD in the 84 patients
diagnosed with ALL between 2001–2007 at our institute who
had good-quality biopsies and compared them with known
sensitive prognostic markers, such as chromosome ploidy and
MRD. The patients had been treated according to study 7 (before
2003, 24 patients, 5 relapses) or study 8 (55 patients, 8 relapses)
of the Australian and New Zealand Children’s Haematology and
Oncology Group, or by some other therapy (5 patients). There is
currently no difference in leukaemia-free survival between the
two Berlin-Frankfurt-Munster (BFM)-based protocols at our
centre; therefore, it seemed reasonable to analyse the patients
as a group. The 84 patients included 44 males and 40 females
who ranged in age from 11 months to 17 years with a median
age of 5 years.
New trephine sections were cut and stained for reticulin
fibrosis, collagen fibrosis and von Willebrand factor (VWF)
immunohistochemistry.6 A hematoxylin and eosin (H&E) stain
was performed to facilitate the determination of cellularity. The
bone marrow fibre content was determined by using a grading
system (modified Bauermeister scale) that included five grades.7
The percentages of patients with different grades of fibrosis were
grade 0: 2.5%, grade 1: 33.3%, grade 2: 37%, grade 3: 19.7%
and grade 4 (collagen þ ): 7.5%. RFD was quantified as
previously described by Nore´n-Nystro¨m et al.1 Briefly, RFD was
calculated using a 121-point eye piece graticule at  400
magnification. The intersections of reticulin fibres with the
crossing points of the graticule were counted in 10 different
areas in the section. RFD was defined as volume of reticulin
fibres per volume reference tissue. Fibrosis grade showed a
strong positive correlation with RFD (Po0.001).
In keeping with earlier reports,3 RFD was significantly higher
in precursor B acute lymphoblastic leukaemia cases than in
T-ALL (Table 1) and there was a negative correlation between
RFD and white blood cell count at diagnosis, with high RFD
being associated with lower initial white blood cell count: mean
10.7 vs 35.3 109/l for lower RFD values. Similarly, there was
a negative correlation between RFD and the percentage of
blast cells in the peripheral blood (Spearman’s correlation
r¼0.278, P¼ 0.018). A higher RFD was also correlated with a
higher cellularity in the bone marrow (r¼ 0.292, P¼ 0.007).
This could imply that some types of leukaemia create a higher
degree of fibrosis than others and that these blasts are then
‘trapped’ in the marrow.
We found no difference between the RFD values of NCI
(National Cancer Institute risk score) high- or low-risk patients,
or between patients who relapsed vs those who continue in
complete remission (Table 1). The most important prognostic
factor in our patients was MRD. PCR-based MRD analysis was
performed on day 33 and 79 in study 8 patients, that is, at the
Table 1 Reticulin fibre density, microvascular density and
prognostic factors
Clinical characteristics RFD MVD
n Mean P n Mean P
Immunophenotype
B-precursor 77 10.1 0.041 75 4.7 NS
T-cell 7 5.2 4 3.2
WBC count at diagnosis
o26.2109/l (Mean value) 63 10.7 0.045 61 4.7 NS
426.2109/l 21 6.5 18 4.4
NCI risk groupa
Standard risk 57 9.4 NS 55 4.6 NS
High risk 20 11.9 20 4.8
Disease statusa
Remission 64 10.5 NS 63 4.6 NS
Relapsed 13 7.7 12 4.9
Cytogenetic groupsa
Normal 9 8.0 0.002 9 4.7 NS
t(12;21) 19 5.9 18 4.2
Trisomies 4,10,17 14 17.0 13 5.0
t(9;22) 2 7.3 2 4.9
Other abnormalities 23 13.6 23 4.7
Ploidya
Hypodiploid 6 3.9 0.006 6 4.7 NS
Diploid 35 8.0 34 4.3
Hyperdiploid (47–50) 13 10.3 13 5.1
High-hyperdiploid (51–61) 22 15.3 21 4.7
MRD groups (day 33–35)a
o103 46 11.0 NS 45 4.7 NS
4103 5 11.6 5 4.0
Abbreviations: MRD, minimal residual disease; MVD, microvessel
density; NS, not significant (40.05); RFD, reticulin fibrin density; WBC,
white blood cell.
aPrognostic grouping for precursor-B ALL patients only (n¼ 77).
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